Top Psychopharmacology Conferences to Attend in 2026

Psychopharmacology is where neuroscience, clinical psychiatry, and pharmaceutical development meet. The researchers and clinicians who work in this field — developing new treatments for depression, schizophrenia, bipolar disorder, anxiety, PTSD, and addiction — depend on a specific set of annual conferences that are very different from general psychiatry or behavioral health events. 

This guide covers the top psychopharmacology conferences in 2026. Each entry includes verified dates, location, audience, and what you gain. We also feature the PubScholars Psychology and Psychiatry Conference 2026 — a hybrid event in Boston with open abstract submission, an international scientific committee, and publication in conference proceedings. 

For broader psychiatry events, see our guide to the top psychiatry conferences in 2026. For behavioral health and mental health events, see our top behavioral health conferences in 2026 guide. 

What is a psychopharmacology conference? 

Psychopharmacology is the scientific study of how drugs affect mood, sensation, thinking, and behaviour — and how those effects can be leveraged to treat psychiatric and neurological disorders. A psychopharmacology conference focuses specifically on this intersection of pharmacology and psychiatry, covering drug mechanisms, clinical trial results, regulatory science, and the neuroscience underlying drug action. 

These conferences are distinct from general psychiatry conferences in two important ways. First, the audience — they draw a higher proportion of basic neuroscientists, clinical trial researchers, pharmaceutical and biotech professionals, and regulatory agency representatives than clinical psychiatry events. Second, the content — the emphasis is on drug development pipelines, mechanism of action research, biomarker validation, and clinical methodology rather than day-to-day clinical practice

Why attend a psychopharmacology conference in 2026? 

2026 is a landmark year in psychopharmacology. GLP-1 receptor agonists for psychiatric conditions, ketamine and psychedelic-assisted therapy trials, AI-driven drug target discovery, precision psychiatry, and next-generation antipsychotics are all generating substantial conference content. For anyone working in this field, staying current requires a presence at the events where these findings are first shared. 

Here is what you gain: 

• Direct access to phase 2 and 3 clinical trial results before publication. 
• CME credits for psychiatrists and CME/CE for NPs and pharmacists at accredited events. 
• Engagement with FDA and international regulatory agencies shaping drug approval pathways. 
• Networking with academic researchers, biotech executives, clinical trialists, and payers. 
• Abstract presentation opportunities for clinical and translational psychopharmacology research. 

Top psychopharmacology conferences in 2026 

1. ★ International Psychology & Psychiatry Conference 2026 — PubScholars (Boston, USA)

Date: November 20–21, 2026 

Location: Hilton Garden Inn Boston Canton110 Royall St, Canton, MA 02021, United States

Theme: “Next-Generation Neuropsychiatry & Mental Health: Integrating AI, Genomics and Clinical Excellence” 

The PubScholars Psychology and Psychiatry Conference 2026 is the most accessible event on this list for psychopharmacology researchers and clinical psychiatrists who want to present their work internationally and get it published. The conference covers psychopharmacology and neuropsychiatry, AI in drug development and mental health, genomics in psychiatric treatment, neuroimaging in pharmacology research, treatment-resistant depression and anxiety, novel therapeutic approaches, and clinical trial methodology. 

Both in-person and virtual attendance are fully supported. Abstracts are reviewed by an international scientific committee and accepted papers are published in official conference proceedings. CPD-accredited credits are available for in-person and virtual attendees. 

Who should attend: Psychiatrists, neuropsychopharmacologists, clinical psychologists, CNS drug development researchers, psychiatric NPs, mental health researchers, and postgraduate students presenting original psychopharmacology research 

CME / CPD Credits: CPD-accredited credits available. Contact info@pubscholars.org 

Abstract submission: https://pubscholars.org/submit-abstract/

Website: https://psychologyconference.pubscholars.org/

 Early Bird Registration closes April 30, 2026. Second round abstract submissions close May 15, 2026. 

 2. ACNP 64th Annual Meeting 2026 — American College of Neuropsychopharmacology (Florida, USA)

Date: January 12–15, 2026 (already held) 

Location: Florida, USA 

 The 64th ACNP Annual Meeting is the flagship event of the American College of Neuropsychopharmacology — the most selective and scientifically rigorous psychopharmacology conference in the USA. ACNP membership is by invitation only, making the annual meeting a genuinely exclusive gathering of the field’s leading academic and clinical researchers. Attendees are eligible for CME credits through joint accreditation by Amedco LLC for ACCME, ACPE, and ANCC. 

The ACNP Annual Meeting covers the full breadth of neuropsychopharmacology — from basic molecular pharmacology and neuroscience to clinical trial outcomes, regulatory science, and the translational research bridging them. Panel discussions, symposia, and poster sessions cover depression, schizophrenia, bipolar disorder, anxiety, addiction, PTSD, and neurodegenerative conditions. The 2026 edition has already taken place. Watch acnp.org for the 65th Annual Meeting dates. 

Who should attend: ACNP members and invited guests: leading academic neuropsychopharmacologists, clinical trial researchers, NIH and FDA representatives, and invited early-career scientists in translational psychiatric pharmacology 

CME Credits: CME credits available — $40.00 charge for scientific registrants to obtain CME credit 

Website: https://acnp.org/

 3.  31st Annual National Psychopharmacology Update 2026 — Nevada Psychiatric Association (Las Vegas, USA)

Date: February 11–14, 2026 (already held) 

Location: Paris Las Vegas Hotel and Casino, Las Vegas, Nevada, USA 

The 31st Annual National Psychopharmacology Update is described as the largest and most comprehensive conference on the psychopharmacological treatment of psychiatric disorders in the United States. Organised by the Nevada Psychiatric Association and held annually at the Paris Las Vegas, the NPA Update offers a year’s worth of CME/CE credits, a full-day pre-conference on regulatory and legal issues in psychiatric practice, daily product theaters, and networking with industry leaders. 

Daily hot breakfast, lunch, and refreshments are included for in-person attendees. The audience spans psychiatrists, nurse practitioners, physician assistants, primary care physicians, students, residents, and fellows. The 2026 edition has already taken place. Watch the Nevada Psychiatric Association website for the 32nd Annual Update dates. 

Who should attend: Psychiatrists, psychiatric NPs, PAs, primary care physicians managing psychiatric conditions, residents and fellows, and all mental health professionals seeking comprehensive psychopharmacology CME 

CME Credits: Year’s worth of CME/CE credits — verify full hours on nevadapsychiatricassociation.com 

Website: 

4. ASCP Annual Meeting 2026 — American Society of Clinical Psychopharmacology (Miami Beach, USA)

Date: May 26–29, 2026 (already held) 

Location: Loews Miami Beach Hotel, Miami Beach, Florida, USA 

Theme: “Psychiatry and AI: Promises, Perils, and Pathways Forward” 

The 2026 ASCP Annual Meeting is widely regarded as the premier annual meeting in clinical psychopharmacology — the event where leaders from academia, the NIH, the FDA, European regulatory agencies, and the pharmaceutical industry gather to discuss the future of neuropsychiatric drug development. It brings together over 1,100 academic and industry investigators, research pharmacists, clinicians, and regulatory representatives. 

The 2026 theme — “Psychiatry and AI: Promises, Perils, and Pathways Forward” — placed artificial intelligence and machine learning squarely at the centre of the psychopharmacology agenda, covering AI in clinical trial design, drug target discovery, biomarker identification, and personalised psychiatric medicine. The 2026 Miami Beach edition has already taken place. Submissions for the 2027 ASCP Annual Meeting open in September 2026. 

Who should attend: Academic psychopharmacologists, CNS drug development researchers, pharmaceutical and biotech industry scientists, NIH and FDA representatives, clinical trialists in psychiatry, and clinical researchers in neuropsychiatric conditions 

CME Credits: CME credits available — verify on ascpp.org 

Website: https://ascpp.org/

 5. CINP 2026 — 37th World Congress of Neuropsychopharmacology (Glasgow, UK)

Date: June 26–29, 2026 

Location: Scottish Events Campus (SEC), Glasgow, Scotland, UK 

Theme: “Advancing Brain Health Together” 

The 37th World Congress of Neuropsychopharmacology — CINP 2026 — returns the World Congress to the UK for the first time in over 25 years. Organised by the Collegium Internationale Neuro-Psychopharmacologicum (CINP) with a joint meeting with the Scandinavian College of Neuropsychopharmacology (SCNP), it is the most globally representative neuropsychopharmacology event of 2026. 

The congress brings together experts from research and medical institutions, leading worldwide regulatory authorities, and major pharmaceutical firms to create a framework for collaboration between academia, industry, and government toward the development and appropriate use of CNS drugs. A dedicated track for early career clinicians and researchers provides networking with global leaders in the field. 

Who should attend: Neuropsychopharmacologists, CNS drug development researchers, academic and industry pharmacologists, regulatory scientists, and early-career researchers in neuropsychiatry and brain pharmacology 

CME Credits: CME/CPD credits available — verify on cinp2026.org 

Website: https://cinp2026.org/

 6. 39th ECNP Congress 2026 — European College of Neuropsychopharmacology (Munich, Germany)

Date: October 10–13, 2026 

Location: ICM – Munich International Congress Center, Munich, Germany (Hybrid — in-person and virtual) 

The 39th ECNP Congress is Europe’s leading conference for the science and treatment of brain disorders — the most important annual neuropsychopharmacology event in Europe. Both in-person and virtual participation are supported, with the congress offering a variety of scientific and industry sessions designed to appeal to a wide range of participants. The 2026 congress features a keynote from Kay M. Tye, a leading researcher in emotional brain circuits and psychiatric pharmacology. 

ECNP covers the full spectrum of neuropsychopharmacology — from basic neuroscience and drug mechanism research to clinical trial data, regulatory science, and the translational bridge between laboratory discoveries and psychiatric therapeutics. For European psychopharmacologists and CNS researchers, ECNP is the most important annual gathering. 

Who should attend: Neuropsychopharmacologists, basic neuroscientists in CNS drug research, clinical psychiatrists engaged in pharmacotherapy research, pharmaceutical industry researchers in Europe, and regulatory scientists in CNS therapeutics 

CME Credits: CME credits available — verify on ecnp.eu/congress2026 

Website: https://www.ecnp.eu/congress2026

7. ISBD Annual Conference 2026 — International Society for Bipolar Disorders (Vancouver, Canada)

Date: September 28–30, 2026 

Location: Vancouver, British Columbia, Canada 

The ISBD Annual Conference 2026 is the premier specialist event for researchers and clinicians working specifically in bipolar disorder — one of the most challenging and underserved areas of psychopharmacology. The conference covers mood stabilisers, antipsychotics in bipolar, lithium pharmacology, novel therapeutics, bipolar biomarkers, neuroimaging in bipolar research, and the pharmacological management of bipolar subtypes and comorbidities. 

For psychopharmacologists whose work focuses on bipolar disorder — whether in basic pharmacology, clinical trials, or prescribing practice — ISBD provides a depth of specialist content that no general psychiatry or psychopharmacology conference can match. 

Who should attend: Bipolar disorder researchers, psychiatrists specialising in mood disorders, psychopharmacologists in bipolar drug development, clinical trialists in mood disorder therapeutics, and clinicians managing complex bipolar presentations 

CME Credits: CME credits available — verify on isbd.org 

Website: https://www.isbd.org/

8. SOBP Annual Meeting 2026 — Society of Biological Psychiatry (USA) 

 

Date: May 2026 — confirm exact dates on sobp.org 

Location: USA — confirm venue on sobp.org 

The SOBP Annual Meeting is the central event for translational biological psychiatry — covering the neuroscience, genetics, and pharmacology underlying psychiatric disorders. For psychopharmacologists, SOBP is where the fundamental mechanisms of drug action in psychiatric conditions are explored alongside clinical applications, making it the most scientifically rigorous event at the basic-clinical interface in the USA. 

The meeting covers the biological basis of depression, schizophrenia, PTSD, bipolar disorder, and anxiety — with a strong emphasis on the translational science that connects molecular pharmacology to clinical drug development. Acceptance at SOBP carries significant academic weight in the field. 

Who should attend: Biological psychiatry researchers, translational neuroscientists, psychopharmacologists in CNS drug development, and psychiatrists with active basic research programmes 

CME Credits: CME credits available — verify on sobp.org 

Website: https://sobp.org/

9. SIRS 2026 — Schizophrenia International Research Society Biennial Congress

Date: 2026 — confirm current dates on sirs.is 

Location: International — confirm venue on sirs.is 

The SIRS Biennial Congress is the most important specialist event in schizophrenia research and psychopharmacology. It brings together schizophrenia researchers, clinical trialists, and pharmacologists from around the world to discuss the neuroscience, genetics, pharmacotherapy, and clinical management of schizophrenia spectrum disorders. For researchers working on antipsychotic drug development, cognitive pharmacology in schizophrenia, or biomarker discovery in psychosis, SIRS is the primary annual peer community. 

The congress covers antipsychotic pharmacology, glutamate and dopamine system research, early psychosis intervention, cognition in schizophrenia, and emerging therapeutic targets including TAAR1 agonists and muscarinic receptor approaches. 

Who should attend: Schizophrenia researchers, antipsychotic drug development scientists, neuropsychopharmacologists working on psychosis, clinical trialists in schizophrenia, and psychiatrists with research interests in schizophrenia spectrum conditions 

CME Credits: CME credits available — verify on sirs.is

10. CTAD 2026 — Clinical Trials on Alzheimer’s Disease Conference (USA)

Date: November 2026 — confirm dates on ctad-alzheimer.com 

Location: USA — confirm venue on ctad-alzheimer.com 

The CTAD Conference is the most focused event in the world for clinical trialists and drug development researchers working specifically on Alzheimer’s disease pharmacotherapy. For psychopharmacologists working on dementia and neurodegeneration therapeutics — including amyloid-targeting agents, tau-based approaches, and neuroprotective pharmacology — CTAD is the year’s most important drug-development-focused event. 

The conference covers phase 2 and 3 Alzheimer’s trial results, regulatory strategy, biomarker-driven trial design, and the translation of scientific discoveries into clinical interventions. Trial readouts presented at CTAD regularly shape prescribing behaviour within months of the conference. 

Who should attend: Alzheimer’s drug development researchers, clinical trialists in neurodegeneration pharmacology, neurologists involved in dementia trial design, biomarker researchers, and regulatory affairs professionals in CNS 

CME Credits: CME credits available — verify on ctad-alzheimer.com :  

Quick comparison: psychopharmacology conferences 2026 at a glance 

Use this table to find the best match for your research focus, location, and timeline. 

 

Conference	Hybrid	Abstract	CME	USA	Date
PubScholars Psych. Conf. 2026 ★	Hybrid	✓	✓	✓	Nov 20–21
ACNP 64th Annual Meeting	In-person	✓	✓	✓	Jan 12–15 ✓held
NPA Update 2026 (Las Vegas)	In-person	Limited	✓	✓	Feb 11–14 ✓held
ASCP 2026 (Miami Beach)	In-person	✓	✓	✓	May 26–29 ✓held
CINP 2026 (Glasgow)	Hybrid	✓	✓	✗	Jun 26–29
ECNP Congress 2026 (Munich)	Hybrid	✓	✓	✗	Oct 10–13
ISBD 2026 (Vancouver)	In-person	✓	✓	✗	Sep 28–30

 

ACNP 2026, NPA Update 2026, and ASCP 2026 have already taken place. All other dates verified as of May 2026. Confirm on official websites before registering. 

How to choose the right psychopharmacology conference for you 

 If you want the most selective USA psychopharmacology gathering 

The ACNP Annual Meeting is the most prestigious and selective psychopharmacology event in the USA — membership and attendance are by invitation. The 64th Annual Meeting has already taken place. Watch acnp.org for the 65th Annual Meeting in January 2027. 

If you want the most comprehensive USA clinical psychopharmacology event 

The ASCP Annual Meeting 2026 (May 26–29, Miami Beach) is the premier open clinical psychopharmacology conference in the USA, bringing together over 1,100 researchers, clinicians, and industry leaders. The 2026 Miami Beach edition has already taken place. Submissions for 2027 open September 2026. 

If you want to present and get published in 2026 

The PubScholars Psychology and Psychiatry Conference 2026 (Nov 20–21, Boston) is the most accessible option for abstract submission, international peer review, and publication in conference proceedings. CPD-accredited credits available. Submit at psychologyconference.pubscholars.org/submit-abstract/. 

If you are based in Europe 

The 39th ECNP Congress (Oct 10–13, Munich) is Europe’s leading neuropsychopharmacology event and the strongest option for European researchers. The CINP 2026 World Congress (Jun 26–29, Glasgow) is the most globally representative event in the calendar. 

If your focus is a specific disorder 

ISBD 2026 (Sep 28–30, Vancouver) for bipolar disorder pharmacology. SIRS 2026 for schizophrenia and antipsychotic research. CTAD 2026 (November, USA) for Alzheimer’s drug development. All offer specialist peer communities that general psychopharmacology conferences cannot replicate. 

If you need the most CME hours in a single event 

The 31st Annual National Psychopharmacology Update (Feb 11–14, Las Vegas) offered a year’s worth of CME/CE credits across four days in 2026 — the highest CME concentration of any event on this list. The 2026 edition has already taken place. 

Useful guides for psychopharmacology researchers and clinicians 

These PubScholars resources will help you prepare: 

• How to write a conference abstract — structure, format, and template for psychopharmacology research 
• Top psychiatry conferences in 2026 — APA, WCP, Psych Congress, EPA, and clinical psychiatry events
• Top behavioral health conferences in 2026 — NatCon, BHT, and the full behavioral health ecosystem 
• Conference papers vs journal papers — decide the right publication route for your pharmacology research 
• Guide to USA conference visa requirements — for international researchers attending conferences in Boston, Miami, or Nashville 

Frequently asked questions — psychopharmacology conferences 2026 

What is a psychopharmacology conference? 

A psychopharmacology conference is a scientific meeting focused on how drugs affect mental processes and behaviour — and how those effects can be used to treat psychiatric and neurological disorders. Unlike general psychiatry conferences, psychopharmacology conferences have a higher proportion of basic scientists, clinical trial researchers, pharmaceutical industry professionals, and regulatory agency representatives. They emphasise drug mechanisms, clinical trial results, biomarker science, and the translational research bridging laboratory findings and clinical use. 

What is the biggest psychopharmacology conference in 2026? 

The ASCP Annual Meeting (May 26–29, Loews Miami Beach Hotel, Florida) is widely regarded as the premier annual meeting in clinical psychopharmacology, bringing together over 1,100 academic and industry researchers, clinicians, NIH representatives, and FDA and European regulatory agency attendees. The 2026 edition has already taken place. 

Is there a psychopharmacology conference still upcoming in 2026? 

Yes. The CINP 2026 World Congress (Jun 26–29, Glasgow), the 39th ECNP Congress (Oct 10–13, Munich), the ISBD Annual Conference (Sep 28–30, Vancouver), CTAD 2026 (November, USA), and the PubScholars Psychology and Psychiatry Conference 2026 (Nov 20–21, Boston, hybrid) all have upcoming dates. The PubScholars conference has abstract submission open at psychologyconference.pubscholars.org/submit-abstract/. 

What is the difference between ACNP, ASCP, CINP, and ECNP? 

ACNP (American College of Neuropsychopharmacology) is a by-invitation-only US society holding the most selective annual meeting in the field. ASCP (American Society of Clinical Psychopharmacology) holds the premier open clinical psychopharmacology meeting in the USA. CINP (Collegium Internationale Neuro-Psychopharmacologicum) holds the World Congress of Neuropsychopharmacology every two years in different global locations. ECNP (European College of Neuropsychopharmacology) holds the largest annual neuropsychopharmacology congress in Europe. All four are separate organisations with different memberships, meeting formats, and geographic focus. 

Which psychopharmacology conference is hybrid in 2026? 

The PubScholars Psychology and Psychiatry Conference 2026 (Nov 20–21, Boston) and the 39th ECNP Congress (Oct 10–13, Munich) are both hybrid events with virtual participation options. The CINP 2026 World Congress (Glasgow) also supports some virtual participation — verify on cinp2026.org. Register for the PubScholars conference at psychologyconference.pubscholars.org. 

Do I need a visa to attend a psychopharmacology conference in the USA? 

International researchers attending ASCP in Miami, ACNP in Florida, or the PubScholars conference in Boston may need a B-1 visa. Your conference organisers can provide a formal invitation letter. Read our complete guide to USA conference visa requirements for the documents you need and how to apply. 

Final thought 

Psychopharmacology in 2026 is advancing faster than at any point in its history. AI-guided drug discovery, precision psychiatry, ketamine and psychedelic clinical trials, next-generation antipsychotics, and GLP-1 receptor research in psychiatric conditions are all generating landmark conference content this year. 

If you are a researcher or clinician in this field looking for a hybrid event with abstract submission open and publication in conference proceedings in 2026, the PubScholars Psychology and Psychiatry Conference 2026 (November 20–21, Aloft Boston Seaport District, Boston, MA) is the most accessible remaining option.